Hisamitsu Pharmaceutical Croissance future

Future contrôle des critères 2/6

Hisamitsu Pharmaceutical devrait augmenter ses bénéfices et son chiffre d'affaires de 11.1% et de 3.7% par an respectivement. Le BPA devrait croître de de 14% par an. Le rendement des capitaux propres devrait être 7.3% dans 3 ans.

Informations clés

11.1%

Taux de croissance des bénéfices

14.0%

Taux de croissance du BPA

Pharmaceuticals croissance des bénéfices	11.7%
Taux de croissance des recettes	3.7%
Rendement futur des capitaux propres	7.3%
Couverture par les analystes	Low
Dernière mise à jour	22 Oct 2024

Mises à jour récentes de la croissance future

Recent updates

Hisamitsu Pharmaceutical (TSE:4530) Has Announced A Dividend Of ¥45.00

Nov 08

We Think Hisamitsu Pharmaceutical (TSE:4530) Can Stay On Top Of Its Debt

Nov 04

Hisamitsu Pharmaceutical's (TSE:4530) Solid Earnings May Rest On Weak Foundations

Oct 17

Hisamitsu Pharmaceutical Co., Inc. (TSE:4530) Not Lagging Market On Growth Or Pricing

Sep 16

Hisamitsu Pharmaceutical's (TSE:4530) Shareholders Will Receive A Bigger Dividend Than Last Year

Aug 20

Hisamitsu Pharmaceutical (TSE:4530) Has Announced That It Will Be Increasing Its Dividend To ¥45.00

Jul 26

Hisamitsu Pharmaceutical (TSE:4530) Is Paying Out A Larger Dividend Than Last Year

Jul 11

Hisamitsu Pharmaceutical's (TSE:4530) Dividend Will Be Increased To ¥45.00

Jun 27

Hisamitsu Pharmaceutical (TSE:4530) Is Increasing Its Dividend To ¥45.00

Jun 13

Why We're Not Concerned About Hisamitsu Pharmaceutical Co., Inc.'s (TSE:4530) Share Price

Apr 09

Here's Why We Think Hisamitsu Pharmaceutical (TSE:4530) Is Well Worth Watching

Mar 18

Prévisions de croissance des bénéfices et des revenus

TSE:4530 - Estimations futures des analystes et données financières antérieures (JPY Millions )
Date	Recettes	Les revenus	Flux de trésorerie disponible	Cash from Op	Moy. Nombre d'analystes
2/28/2027	165,000	19,200	23,427	N/A	1
2/28/2026	157,500	15,900	19,818	N/A	1
2/28/2025	154,500	17,200	5,208	N/A	1
8/31/2024	150,185	14,650	176	18,593	N/A
5/31/2024	145,420	14,708	N/A	N/A	N/A
2/29/2024	141,706	13,969	5,152	18,188	N/A
11/30/2023	139,276	14,330	N/A	N/A	N/A
8/31/2023	135,688	13,655	2,186	12,416	N/A
5/31/2023	134,033	14,160	N/A	N/A	N/A
2/28/2023	128,330	11,742	4,819	12,727	N/A
11/30/2022	125,411	12,962	N/A	N/A	N/A
8/31/2022	121,261	11,160	8,832	12,698	N/A
5/31/2022	118,825	8,927	N/A	N/A	N/A
2/28/2022	120,193	9,658	15,006	19,199	N/A
11/30/2021	120,351	9,746	N/A	N/A	N/A
8/31/2021	120,135	10,559	12,153	15,796	N/A
5/31/2021	117,389	11,499	N/A	N/A	N/A
2/28/2021	114,510	9,250	1,901	5,289	N/A
11/30/2020	122,736	8,996	N/A	N/A	N/A
8/31/2020	130,517	14,839	19,468	23,638	N/A
5/31/2020	136,641	16,894	N/A	N/A	N/A
2/29/2020	140,992	18,694	23,669	27,395	N/A
11/30/2019	139,912	21,295	N/A	N/A	N/A
8/31/2019	137,425	17,594	12,616	16,497	N/A
5/31/2019	139,142	17,665	N/A	N/A	N/A
2/28/2019	143,408	19,204	12,109	15,772	N/A
11/30/2018	140,891	16,608	N/A	N/A	N/A
8/31/2018	143,791	18,891	18,299	21,587	N/A
5/31/2018	145,288	18,897	N/A	N/A	N/A
2/28/2018	147,870	19,119	N/A	30,453	N/A
11/30/2017	145,749	17,895	N/A	N/A	N/A
8/31/2017	144,941	20,495	N/A	25,077	N/A
5/31/2017	143,853	19,540	N/A	N/A	N/A
2/28/2017	145,925	20,395	N/A	19,910	N/A
11/30/2016	149,298	20,806	N/A	N/A	N/A
8/31/2016	153,871	17,694	N/A	27,819	N/A
5/31/2016	160,325	18,778	N/A	N/A	N/A
2/29/2016	161,852	17,784	N/A	30,923	N/A
11/30/2015	164,086	19,626	N/A	N/A	N/A
8/31/2015	162,119	18,586	N/A	25,757	N/A
5/31/2015	158,667	18,321	N/A	N/A	N/A
2/28/2015	156,743	18,784	N/A	23,232	N/A
11/30/2014	150,446	16,645	N/A	N/A	N/A
8/31/2014	150,305	17,250	N/A	29,649	N/A
5/31/2014	151,326	17,841	N/A	N/A	N/A
2/28/2014	150,635	21,357	N/A	35,845	N/A
11/30/2013	150,544	22,976	N/A	N/A	N/A

Prévisions de croissance des analystes

Taux de revenus par rapport au taux d'épargne: La croissance des bénéfices prévue de 4530 ( 11.1% par an) est supérieure au taux d'épargne ( 0.3% ).

Bénéfices vs marché: Les bénéfices de 4530 ( 11.1% par an) devraient croître plus rapidement que le marché JP ( 7.9% par an).

Croissance élevée des bénéfices: Les bénéfices de 4530 devraient augmenter, mais pas de manière significative.

Chiffre d'affaires vs marché: Le chiffre d'affaires de 4530 ( 3.7% par an) devrait croître plus lentement que le marché de JP ( 4.2% par an).

Croissance élevée des revenus: Le chiffre d'affaires de 4530 ( 3.7% par an) devrait croître plus lentement que 20% par an.

Prévisions de croissance du bénéfice par action

Rendement futur des capitaux propres

ROE futur: Le retour sur capitaux propres de 4530 devrait être faible dans 3 ans ( 7.3 %).

Hisamitsu Pharmaceutical Croissance future

Future contrôle des critères 2/6

Informations clés

Mises à jour récentes de la croissance future

Price target decreased by 15% to JP¥4,250

Price target increased by 16% to JP¥4,450

Hisamitsu Pharmaceutical Co., Inc. Provides Consolidated Earnings Guidance for the Fiscal Year Ending February 29, 2024

Hisamitsu Pharmaceutical Co., Inc. Provides Consolidated Earnings Guidance for the Fiscal Year Ending February 28, 2023

Price target increased to JP¥3,700

Price target increased to JP¥3,700

Recent updates

Hisamitsu Pharmaceutical (TSE:4530) Has Announced A Dividend Of ¥45.00

First half dividend of JP¥45.00 announced

We Think Hisamitsu Pharmaceutical (TSE:4530) Can Stay On Top Of Its Debt

Hisamitsu Pharmaceutical's (TSE:4530) Solid Earnings May Rest On Weak Foundations

Second quarter 2025 earnings: EPS exceeds analyst expectations while revenues lag behind

Hisamitsu Pharmaceutical Co., Inc. (TSE:4530) Not Lagging Market On Growth Or Pricing

Upcoming dividend of JP¥45.00 per share

Hisamitsu Pharmaceutical's (TSE:4530) Shareholders Will Receive A Bigger Dividend Than Last Year

Hisamitsu Pharmaceutical Co., Inc. to Report Q2, 2025 Results on Oct 10, 2024

Hisamitsu Pharmaceutical (TSE:4530) Has Announced That It Will Be Increasing Its Dividend To ¥45.00

First quarter 2025 earnings: EPS exceeds analyst expectations while revenues lag behind

Hisamitsu Pharmaceutical (TSE:4530) Is Paying Out A Larger Dividend Than Last Year

Hisamitsu Pharmaceutical Co., Inc. Provides Commemorative Dividend for the Fiscal Year Ending February 28, 2025

Hisamitsu Pharmaceutical's (TSE:4530) Dividend Will Be Increased To ¥45.00

Hisamitsu Pharmaceutical (TSE:4530) Is Increasing Its Dividend To ¥45.00

Final dividend of JP¥45.00 announced

Hisamitsu Pharmaceutical Co., Inc. to Report Q1, 2025 Results on Jul 11, 2024

Hisamitsu Pharmaceutical Co., Inc. (TSE:4530) announces an Equity Buyback for 2,400,000 shares, representing 3.17% for ¥8,901.6 million.

Full year 2024 earnings: EPS misses analyst expectations

Hisamitsu Pharmaceutical Co., Inc., Annual General Meeting, May 23, 2024

Why We're Not Concerned About Hisamitsu Pharmaceutical Co., Inc.'s (TSE:4530) Share Price

Here's Why We Think Hisamitsu Pharmaceutical (TSE:4530) Is Well Worth Watching

Hisamitsu Pharmaceutical Co., Inc. to Report Fiscal Year 2024 Results on Apr 11, 2024

Upcoming dividend of JP¥42.50 per share

Price target decreased by 15% to JP¥4,250

Third quarter 2024 earnings released: EPS: JP¥48.25 (vs JP¥37.89 in 3Q 2023)

Hisamitsu Pharmaceutical Co., Inc. Announces Dividend for the Second Quarter and Provides Dividend Guidance for the Full Year Ending February 29, 2024

Hisamitsu Pharmaceutical Co., Inc. to Report Q3, 2024 Results on Jan 11, 2024

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Upcoming dividend of JP¥42.50 per share at 1.8% yield

Hisamitsu Pharmaceutical Co., Inc. to Report Q2, 2024 Results on Oct 06, 2023

Price target increased by 16% to JP¥4,450

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Hisamitsu Pharmaceutical Co., Inc. (TSE:4530) announces an Equity Buyback for 2,000,000 shares, representing 2.57% for ¥10,000 million.

Hisamitsu Pharmaceutical Co., Inc. Provides Consolidated Earnings Guidance for the Fiscal Year Ending February 29, 2024

Full year 2023 earnings: EPS misses analyst expectations

Hisamitsu Pharmaceutical Co., Inc. to Report Q1, 2024 Results on Jul 13, 2023

Full year 2023 earnings: EPS misses analyst expectations

Upcoming dividend of JP¥42.25 per share at 2.1% yield

Hisamitsu Pharmaceutical Co., Inc. to Report Fiscal Year 2023 Results on Apr 13, 2023

Third quarter 2023 earnings released: EPS: JP¥37.89 (vs JP¥14.91 in 3Q 2022)

Hisamitsu Pharmaceutical Co., Inc. Provides Consolidated Earnings Guidance for the Fiscal Year Ending February 28, 2023

Price target increased to JP¥3,700

Less than half of directors are independent

Price target increased to JP¥3,700

Consensus forecasts updated

Hisamitsu Pharmaceutical Co., Inc. to Report Q3, 2023 Results on Jan 12, 2023

Second quarter 2023 earnings: EPS exceeds analyst expectations

Hisamitsu Pharmaceutical Co., Inc. (TSE:4530) announces an Equity Buyback for 2,000,000 shares, representing 2.51% for ¥10,000 million.

Hisamitsu Pharmaceutical Co., Inc. Announces Dividend for the Second Quarter Ended August 31, 2022, Payable on Nov. 9, 2022; Provides Dividend Guidance for the full year ending February 28, 2023

Hisamitsu Pharmaceutical Co., Inc. to Report Q2, 2023 Results on Oct 12, 2022

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Hisamitsu Pharmaceutical Co., Inc. Provides Dividend Guidance for the Second Quarter and Full Year Ending February 28, 2023

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Hisamitsu Pharmaceutical Co., Inc. to Report Q1, 2023 Results on Jul 07, 2022

Less than half of directors are independent

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Hisamitsu Pharmaceutical Co., Inc. Provides Consolidated Earnings Guidance for the Year Ending February 28, 2023

Upcoming dividend of JP¥42.00 per share

Upcoming dividend of JP¥42.00 per share

Hisamitsu Pharmaceutical Co., Inc. to Report Fiscal Year 2022 Results on Apr 07, 2022

Consensus EPS estimates fall by 19%

Price target decreased to JP¥3,600

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Hisamitsu Pharmaceutical Co., Inc. Provides Consolidated Earnings Guidance for the Year Ending February 28, 2022

Second quarter 2022 earnings released: EPS JP¥32.30 (vs JP¥43.82 in 2Q 2021)

Upcoming dividend of JP¥42.00 per share

First quarter 2022 earnings released: EPS JP¥28.90 (vs JP¥1.38 in 1Q 2021)

Full year 2021 earnings released: EPS JP¥113 (vs JP¥228 in FY 2020)